Analysts Issue Forecasts for RANI Q1 Earnings

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) – Equities researchers at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Rani Therapeutics in a note issued to investors on Friday, March 27th. HC Wainwright analyst B. Folkes anticipates that the company will earn ($0.06) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Rani Therapeutics’ current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Rani Therapeutics’ Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.07) EPS and FY2030 earnings at ($0.30) EPS.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Rani Therapeutics in a research report on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $8.33.

Rani Therapeutics Price Performance

Shares of RANI stock opened at $0.81 on Monday. Rani Therapeutics has a fifty-two week low of $0.39 and a fifty-two week high of $3.87. The stock has a market cap of $98.50 million, a P/E ratio of -1.37 and a beta of 0.39. The business has a fifty day simple moving average of $1.27 and a 200-day simple moving average of $1.32.

Rani Therapeutics (NASDAQ:RANI) last issued its quarterly earnings data on Thursday, March 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.04). The company had revenue of $1.46 million during the quarter, compared to analysts’ expectations of $5.00 million.

Institutional Trading of Rani Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. RA Capital Management L.P. acquired a new position in Rani Therapeutics during the fourth quarter worth approximately $11,475,000. AWM Investment Company Inc. acquired a new position in shares of Rani Therapeutics in the 4th quarter valued at $8,775,000. SymBiosis Capital Partners LLC purchased a new stake in shares of Rani Therapeutics during the 4th quarter valued at $8,505,000. Armistice Capital LLC purchased a new stake in shares of Rani Therapeutics during the 2nd quarter valued at $1,619,000. Finally, Siren L.L.C. acquired a new stake in shares of Rani Therapeutics during the 4th quarter worth $2,700,000. 30.19% of the stock is currently owned by hedge funds and other institutional investors.

Rani Therapeutics Company Profile

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.

Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.